Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Bristol Myers Squibb International Corporation

Enrolment target

Start

10 Aug 2023

Objective Response Rate (ORR) in Cohort B, C, and Cohort D, Radiographic Progression-Free Survival (rPFS)

Age 18 Years to any · Sex: Male

Always speak to your GP or specialist before deciding to take part in a study.